Browsing by Subject "CGM"

Now showing 1 - 3 of 3
  • Thumbnail Image
    Item
    ISPAD Clinical Practice Consensus Guidelines 2022: Diabetes technologies: Glucose monitoring
    (Wiley, 2022) Tauschmann, Martin; Forlenza, Gregory; Hood, Korey; Cardona-Hernandez, Roque; Giani, Elisa; Hendrieckx, Christel; DeSalvo, Daniel J.; Laffel, Lori M.; Saboo, Banshi; Wheeler, Benjamin J.; Laptev, Dmitry N.; Yarhere, Iroro; DiMeglio, Linda A.; Pediatrics, School of Medicine
  • Thumbnail Image
    Item
    The Use of Continuous Glucose Monitoring to Diagnose Stage 2 Type 1 Diabetes
    (Sage, 2025-05-30) Mader, Julia K.; Wong, Jenise C.; Freckmann, Guido; Garcia-Tirado, Jose; Hirsch, Irl B.; Johnson, Suzanne Bennett; Kerr, David; Kim, Sun H.; Lal, Rayhan; Montaser, Eslam; O'Donnell, Holly; Pleus, Stefan; Shah, Viral N.; Ayers, Alessandra T.; Ho, Cindy N.; Biester, Torben; Dovc, Klemen; Farrokhi, Farnoosh; Fleming, Alexander; Gillard, Pieter; Heinemann, Lutz; López-Díez, Raquel; Maahs, David M.; Mathieu, Chantal; Quandt, Zoe; Rami-Merhar, Birgit; Wolf, Wendy; Klonoff, David C.; Medicine, School of Medicine
    This consensus report evaluates the potential role of continuous glucose monitoring (CGM) in screening for stage 2 type 1 diabetes (T1D). CGM offers a minimally invasive alternative to venous blood testing for detecting dysglycemia, facilitating early identification of at-risk individuals for confirmatory blood testing. A panel of experts reviewed current evidence and addressed key questions regarding CGM's diagnostic accuracy and screening protocols. They concluded that while CGM cannot yet replace blood-based diagnostics, it holds promise as a screening tool that could lead to earlier, more effective intervention. Metrics such as time above range >140 mg/dL could indicate progression risk, and artificial intelligence (AI)-based modeling may enhance predictive capabilities. Further research is needed to establish CGM-based diagnostic criteria and refine screening strategies to improve T1D detection and intervention.
  • Thumbnail Image
    Item
    Twelve-month Psychosocial Outcomes of Continuous Glucose Monitoring with Behavioral Support in Parents of Young Children with Type 1 Diabetes
    (Wiley, 2023) Commissariat, Persis V.; DiMeglio, Linda A.; Kanapka, Lauren G.; Laffel, Lori M.; Miller, Kellee M.; Anderson, Barbara J.; Hilliard, Marisa E.; Strategies to Enhance New CGM Use in Early Childhood (SENCE) Study Group; Pediatrics, School of Medicine
    Aim: Managing type 1 diabetes in young children can cause significant stress for parents. Continuous glucose monitoring (CGM) may reduce parental burden. The Strategies to Enhance CGM Use in Early Childhood (SENCE) trial randomized parents of children (ages 2 to <8 years) with type 1 diabetes to CGM with family behavioural intervention (CGM + FBI), CGM alone (Standard-CGM) or blood glucose monitoring for 26 weeks before receiving CGM + FBI (BGM-Crossover). This report assesses changes in psychosocial outcomes for all groups over 52 weeks. Methods: CGM + FBI (n = 45), Standard-CGM (n = 42) and BGM-Crossover (n = 44) participants completed psychosocial assessments at baseline, 26 weeks and 52 weeks. Repeated measures linear regression models evaluated change within and between treatment groups. Results: The BGM-Crossover group reported improved diabetes burden (Δ -6.9, 95% CI [-11.3, -2.6], p = 0.003), fear of hypoglycaemia (Δ -6.4, CI [-10.1, -2.6], p = 0.002) and technology satisfaction (Δ 7.3, CI [2.4, 12.2], p = 0.005) from 26 to 52 weeks, similar to published findings in the CGM + FBI group over the first 26 weeks. The Standard-CGM group reported increased technology satisfaction (Δ 7.3, CI [0.6, 14.0], p = 0.027) from baseline to 52 weeks. The CGM + FBI group reported less diabetes burden and fear of hypoglycaemia from baseline to 52 weeks, but changes were not statistically significant. Scores from 26 to 52 weeks did not deteriorate. Conclusions: Parents demonstrated psychosocial benefits following FBI that appeared to maintain without additional intervention. CGM-focused education with behavioural support likely helps parents of young children with type 1 diabetes reduce burden and worry in the short- and long-term.